Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) FCF Margin (2016 - 2025)

Historic FCF Margin for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to 6127.12%.

  • Celldex Therapeutics' FCF Margin fell 49421400.0% to 6127.12% in Q2 2025 from the same period last year, while for Sep 2025 it was 6988.15%, marking a year-over-year decrease of 53876700.0%. This contributed to the annual value of 2275.2% for FY2024, which is 6900000.0% down from last year.
  • As of Q2 2025, Celldex Therapeutics' FCF Margin stood at 6127.12%, which was down 49421400.0% from 7865.47% recorded in Q1 2025.
  • Celldex Therapeutics' FCF Margin's 5-year high stood at 346.93% during Q2 2021, with a 5-year trough of 26270.51% in Q1 2024.
  • Moreover, its 5-year median value for FCF Margin was 3734.54% (2021), whereas its average is 6574.54%.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by -232556200bps in 2024, then soared by 184050500bps in 2025.
  • Celldex Therapeutics' FCF Margin (Quarter) stood at 4454.19% in 2021, then surged by 69bps to 1363.73% in 2022, then soared by 41bps to 803.66% in 2023, then plummeted by -252bps to 2830.13% in 2024, then tumbled by -116bps to 6127.12% in 2025.
  • Its FCF Margin was 6127.12% in Q2 2025, compared to 7865.47% in Q1 2025 and 2830.13% in Q4 2024.